Fate Therapeutics
12278 Scripps Summit Drive
San Diego
California
92131
United States
Tel: 858.875.1800
Website: http://www.fatetherapeutics.com/
Email: info@fatetherapeutics.com
About Fate Therapeutics
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology pipeline includes off-the-shelf, iPSC-derived natural killer (NK) cell and T-cell product candidates, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens using chimeric antigen receptors (CARs). Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
155 articles with Fate Therapeutics
-
Fate Therapeutics to Present at Upcoming March 2023 Investor Conferences
3/3/2023
Fate Therapeutics, Inc. announced that the Company will participate in the following upcoming investor conferences:
-
Fate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
2/28/2023
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2022.
-
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2022 Financial Results
2/13/2023
Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE) today announced that the Company will host a conference call and live audio webcast on Tuesday, February 28, 2023 at 5:00 PM ET to report its fourth quarter and full year 2022 financial results and provide a corporate update.
-
Thursday, Fate Therapeutics announced it terminated the 2020 collaboration agreement with Johnson & Johnson’s biopharma subsidiary Janssen.
-
Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next-Generation Programs, and Key 2023 Initiatives
1/5/2023
Fate Therapeutics, Inc. announced that it has declined a proposal from Janssen Biotech, Inc. for continuation of the collaboration and option agreement between the parties on revised terms and conditions and, as a result, the agreement has been terminated and all collaboration activities will be wound down in the first quarter of 2023.
-
Fate Therapeutics Features Multiple Novel Approaches to Eliminate Conditioning Chemotherapy for Off-the-shelf, iPSC-derived Cell Therapies at 2022 ASH Annual Meeting
12/13/2022
Fate Therapeutics, Inc. presented preclinical data of several novel strategies designed to enable administration of off-the-shelf cell-based cancer immunotherapies without conditioning chemotherapy at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.
-
Fate Therapeutics Highlights iPSC-derived, Off-the-shelf CAR NK Cell Programs for Multiple Myeloma at 2022 ASH Annual Meeting
12/10/2022
Fate Therapeutics, Inc. presented interim clinical data from the dose-escalation stage of its ongoing Phase 1 study of FT576 for patients with relapsed / refractory multiple myeloma at the 64th American Society of Hematology Annual Meeting and Exposition.
-
Fate Therapeutics Announces Clinical Safety and Activity Data of First-ever iPSC-derived CAR T-cell Therapy at 2022 ASH Annual Meeting
12/10/2022
Fate Therapeutics, Inc. presented interim clinical data from the dose-escalation stage of its ongoing Phase 1 study of FT819 for patients with relapsed / refractory B-cell lymphoma at the 64th American Society of Hematology Annual Meeting and Exposition.
-
Fate Therapeutics Announces Exercise by ONO Pharmaceutical of Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors
11/7/2022
Fate Therapeutics, Inc. announced that ONO Pharmaceutical Co., Ltd. has exercised its option to FT825/ONO-8250, a multiplexed-engineered, iPSC-derived, chimeric antigen receptor T-cell product candidate targeting human epidermal growth factor receptor 2 -expressing solid tumors.
-
Fate Therapeutics to Present at Upcoming November 2022 Investor Conferences
11/4/2022
Fate Therapeutics, Inc. announced that the Company will present at the following upcoming investor conferences.
-
Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the 2022 ASH Annual Meeting
11/3/2022
Fate Therapeutics, Inc. announced that fourteen presentations for the Company’s induced pluripotent stem cell product platform were accepted for presentation at the 64th American Society of Hematology Annual Meeting and Exposition being held in New Orleans, Louisiana, or virtually, December 10-13, 2022.
-
Fate Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Operational Progress
11/3/2022
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, reported business highlights and financial results for the third quarter ended September 30, 2022.
-
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2022 Financial Results
10/24/2022
Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE) today announced that the Company will host a conference call and live audio webcast on Thursday, November 3, 2022 at 5:00 PM ET to report its third quarter 2022 financial results and provide a corporate update.
-
Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the Society for Immunotherapy of Cancer 37th Annual Meeting
10/5/2022
Fate Therapeutics, Inc. announced that the Company will present clinical and preclinical data for the Company’s induced pluripotent stem cell product platform at the Society for Immunotherapy of Cancer 37th Annual Meeting being held in Boston, MA, and virtually, November 8-12, 2022.
-
Fate Therapeutics to Participate at Upcoming September Investor Conferences
9/2/2022
Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will participate in the following upcoming investor conferences.
-
Finding a job right out of college can seem like a daunting task. To help, BioSpace has compiled a list of the top companies hiring new grads for entry-level roles.
-
Fate Therapeutics Announces Preclinical Publication Highlighting Derivation of CD8αβ T Cells from TCR-CAR+ Induced Pluripotent Stem Cells
8/9/2022
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced the publication of preclinical study results demonstrating the successful generation, durable anti-tumor response, and functional persistence of TCR-CAR+ iPSC-derived CD8αβ T cells from induced pluripotent stem cells (iPSCs).
-
Fate Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Operational Progress
8/3/2022
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, reported business highlights and financial results for the second quarter ended June 30, 2022.
-
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2022 Financial Results
7/25/2022
Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), today announced that the Company will host a conference call and live audio webcast on Wednesday, August 3, 2022 at 5:00 PM ET to report its second quarter 2022 financial results and provide a corporate update.
-
Fate Therapeutics Appoints Brian T. Powl as Chief Commercial Officer
6/30/2022
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that Brian T. Powl has been appointed Chief Commercial Officer.